These robust findings revealed that clinical outcome of TKI treated mutant EGFR NSCLC individuals who harbored BIM deletion polymorphism was inferior to those carrying BIM wild polymorphism in Asian population. Here, EGFR is linked to non-small cell lung carcinoma.